NCT04903197 - Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Interventions

DRUG

VAY736

VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.

DRUG

lenalidomide

Immune-modulatory agent that enhances activation of NK cells.

Trial Locations (10)

3004

Novartis Investigative Site, Melbourne

20089

Novartis Investigative Site, Rozzano

25123

Novartis Investigative Site, Brescia

119228

Novartis Investigative Site, Singapore

200032

Novartis Investigative Site, Shanghai

300020

Novartis Investigative Site, Tianjin

04103

Novartis Investigative Site, Leipzig

990 9585

Novartis Investigative Site, Yamagata

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul